Get the Weekly Intelligence Brief — top committee picks every Sunday.
TVTX · NASDAQ · STOCK

Travere Therapeutics, Inc.

Healthcare Updated August 11, 2026
$60.25
52W $17.05 – $66.24
62/100
$5.60B
-133.8
1.04
AI Committee Verdict
Buy
62/100
Conviction: Contested · 75% agreement · 4 analysts
Contested

Is TVTX Bullish or Bearish?

Bullish. Innellis AI committee rates Travere Therapeutics, Inc. (TVTX) Buy with a composite score of 62/100 , based on 4 analysts with 75% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.14 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.86 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 17.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • Bollinger bandwidth of 17.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
62/100
Agreement
75%
Analysts
4
Conviction
Contested
Sector Rank
Top 33%
of 192 Healthcare peers
Technical Analyst bullish
69 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 17.2% signals elevated volatility
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 17 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
59.0
Neutral
MACD Histogram
0.300
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.77
Inside Bands
Price vs Moving Averages
EMA 9
$59.55 Above
EMA 21
$58.03 Above
EMA 50
$54.50 Above
EMA 200
$41.32 Above

Fundamental Analysis

Valuation
64
Profitability
25
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio -133.8×
P/B Ratio 229.52×
PEG Ratio 1.17
Dividend Yield 0.00%
52W High $66.24
52W Low $17.05
Quality & Growth
ROE -2224.7%
ROA -422.1%
Gross Margin 9440.6%
Operating Margin -684.2%
Revenue Growth YoY
Debt / Equity 25.16
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -133.8 (inexpensive relative to a 15-40x range); Price-to-book of 229.5x; PEG ratio of 1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -22.2%; Return on assets of -4.2%; Net margin of -7.4%; Gross margin of 94.4%; Current ratio of 4.05 (healthy short-term liquidity); Debt-to-equity of 25.16; Free cash flow per share is positive (0.79); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full TVTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore TVTX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime